Abstract | BACKGROUND: METHODS AND RESULTS: Eight patients were treated with epoprostenol for 387.3±116.3 days (range, 102-1,063 days), who were finally diagnosed with PVOD or PCH by pathological examination. The maximum dose of epoprostenol given was 55.3±10.7 ng·kg(-1)·min(-1) (range, 21.0-110.5 ng·kg(-1)·min(-1)). With careful management, epoprostenol therapy significantly improved the 6-min walk distance (97.5±39.2 to 329.4±34.6 m, P<0.001) and plasma brain natriuretic peptide levels (381.3±136.8 to 55.2±14.4 pg/ml, P<0.05). The cardiac index significantly increased from 2.1±0.1 to 2.9±0.3 L·min(-1)·m(-2) (P<0.05). However, pulmonary artery pressure and pulmonary vascular resistance were not significantly reduced. For 4 patients, epoprostenol therapy acted as a bridge to lung transplantation. For the other patients who had no chance to undergo lung transplantation, epoprostenol therapy was applied for 528.0±216.6 days and the maximum dose was 63.9±19.0 ng·kg(-1)·min(-1). CONCLUSIONS: This study data suggest that cautious application of epoprostenol can be considered as a therapeutic option in patients with PVOD and PCH.
|
Authors | Aiko Ogawa, Katsumasa Miyaji, Ichiro Yamadori, Yoko Shinno, Aya Miura, Kengo F Kusano, Hiroshi Ito, Hiroshi Date, Hiromi Matsubara |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 76
Issue 7
Pg. 1729-36
( 2012)
ISSN: 1347-4820 [Electronic] Japan |
PMID | 22481098
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Antihypertensive Agents
- Biomarkers
- Vasodilator Agents
- Natriuretic Peptide, Brain
- Epoprostenol
|
Topics |
- Adolescent
- Adult
- Antihypertensive Agents
(adverse effects, therapeutic use)
- Biomarkers
(blood)
- Blood Pressure
(drug effects)
- Child
- Epoprostenol
(adverse effects, therapeutic use)
- Exercise Tolerance
(drug effects)
- Female
- Hemangioma, Capillary
(blood, complications, diagnosis, drug therapy, physiopathology)
- Humans
- Hypertension, Pulmonary
(blood, diagnosis, drug therapy, etiology, physiopathology)
- Japan
- Lung Neoplasms
(blood, complications, diagnosis, drug therapy, physiopathology)
- Lung Transplantation
- Male
- Natriuretic Peptide, Brain
(blood)
- Pulmonary Veno-Occlusive Disease
(blood, complications, drug therapy, physiopathology)
- Recovery of Function
- Time Factors
- Treatment Outcome
- Vascular Resistance
(drug effects)
- Vasodilator Agents
(adverse effects, therapeutic use)
|